BayTech Venture Capital invests in Mobile Visual Radio Company Spodradio
Munich, December 15, 2005 - BayTech Venture Capital, the Munich-based early-stage venture capital firm, has made a sole €2 million series A investment in Stuttgart, Germany-based Spodradio, whose product enables users to turn their mobile phones into a music jukebox with hundreds of interactive visual radio channels. The deal is the first investment made from BayTech’s €86 million fund, BayTech Venture Capital II fund, closed in July.
The investment will allow Spodradio to support the market entry of its mobile visual radio platform across Germany. 25 radio stations including BigFM, Rs2, Radio 7, RMN Radio, Club977 and Digitally Imported
The article [click here]
IntegraGen completes EUR 8 Mio. Financing to progress genetic Tests for complex Diseases, including Autism and Metabolic Syndrome
Paris, France, 17 November 17, 2005 ... IntegraGen, a company focused on the development and delivery of genetic tests for complex diseases has announced the successful closing of its second financing round raising €8 million (.6 million), which brings the total capital raised by IntegraGen to date to €20 million ( million). The international syndicate of investors comprising both existing and new investors participating included CDC Entreprises Innovation, AGF Private Equity, Bioam, SGAM Alternative Investments, and Baytech Venture Capital.
Commenting on the financing, Dr.Jan Mous, president and CEO said: "We are delighted that existing
The article [click here]
QuesCom named to the 2005 “Pulver 100”
Increased real-world deployment and significant growth rates help to Secure Ranking on pulver 100
October 4, 2005: QuesCom, the leading European provider of GSM Gateways for IP and ISDN environments today announced that it has been named to the 2005 “pulver 100” – the Voice over IP industry’s premiere listing of privately held growth companies that represent the future of the communications ecosystem. QuesCom has been named to the list due to its increased real-world deployment and significant growth rate.
QuesCom’s products include the QuesCom 400 IP/GSM gateway which integrates seamlessly into today’s IP environments and delivers mobility services as well as immediate reductions of between 50 and 90 per cent on corporate phone bills by
The article [click here]
Europe Technologies was certified ISO 9001
October, 2005: Europe Technologies was certified ISO 9001 during the summer this year. All requirements stated in the standard ISO 9001, issue 2000 are applicable.
Europe Technologies aims to satisfy all its customers by delivering reliable products on time which meet the customer's performance and quality requirement.
The article [click here]
BayTech Venture Capital Raises Second Fund –
Closing of € 86 million
Munich, July 14, 2005.
BayTech Venture Capital, the Munich-based early-stage venture capital firm, has raised € 86 million for its BayTech Venture Capital II fund, which will make investments in Western Europe with a primary focus on Germany and France.
The new fund received commitments from large institutional investors – including the international banks and insurance companies that have already contributed to BayTech’s first fund. Targeted investment sectors are Technology – Communications, Software, Semiconductors, Electronics – and Life Sciences.
BayTech Venture Capital’s Managing Partner Rolf Schneider-Günther explains: „We appreciate
The article [click here]
BayTech Venture Capital invests in elbion AG
München / Radebeul, Germany – January 2005: BayTech Venture Capital invests in a € 25 million first round in Radebeul near Dresden-based elbion AG. The private placement was co-led by 3i (Munich, Germany), Burrill & Company (San Francisco, USA) and DVC Deutsche Venture Capital (Munich, Germany). Also participating in the round were AGF Private Equity (Paris, France), Quintiles PharmaBio Development (Durham, North Carolina, USA) and Marubeni Corporation (Tokyo, Japan, and New York, USA).
About elbion AG
Founded in 2002 as a management buy-out from Degussa’s pharmaceutical group, elbion discovers and develops small molecules against inflammatory
The article [click here]
